Adverum Biotechnologies (ADVM) Competitors $2.68 +0.14 (+5.51%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. CRGX, CYBN, EDIT, EPRX, ENGN, TLSA, CTMX, OGI, GNFT, and FDMTShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include CARGO Therapeutics (CRGX), Cybin (CYBN), Editas Medicine (EDIT), Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors CARGO Therapeutics Cybin Editas Medicine Eupraxia Pharmaceuticals enGene Tiziana Life Sciences CytomX Therapeutics Organigram Global GENFIT 4D Molecular Therapeutics CARGO Therapeutics (NASDAQ:CRGX) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Do analysts prefer CRGX or ADVM? CARGO Therapeutics currently has a consensus target price of $15.40, suggesting a potential upside of 235.88%. Adverum Biotechnologies has a consensus target price of $23.80, suggesting a potential upside of 788.06%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than CARGO Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CARGO Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to CRGX or ADVM? In the previous week, CARGO Therapeutics had 14 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 14 mentions for CARGO Therapeutics and 0 mentions for Adverum Biotechnologies. CARGO Therapeutics' average media sentiment score of 0.47 beat Adverum Biotechnologies' score of 0.00 indicating that CARGO Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CARGO Therapeutics Neutral Adverum Biotechnologies Neutral Which has preferable valuation & earnings, CRGX or ADVM? Adverum Biotechnologies has higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCARGO TherapeuticsN/AN/A-$167.50M-$4.62-0.99Adverum Biotechnologies$1M55.99-$130.93M-$6.40-0.42 Is CRGX or ADVM more profitable? CARGO Therapeutics' return on equity of -45.93% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets CARGO TherapeuticsN/A -45.93% -39.58% Adverum Biotechnologies N/A -130.53%-66.31% Which has more risk & volatility, CRGX or ADVM? CARGO Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Do institutionals and insiders hold more shares of CRGX or ADVM? 93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 2.9% of CARGO Therapeutics shares are owned by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAdverum Biotechnologies beats CARGO Therapeutics on 8 of the 14 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.88M$2.96B$5.58B$9.01BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-0.4221.4727.5120.20Price / Sales55.99259.84415.84172.51Price / CashN/A41.8337.0657.97Price / Book0.797.788.085.61Net Income-$130.93M-$55.05M$3.17B$248.50M7 Day Performance12.37%5.38%3.57%4.92%1 Month Performance-3.94%3.87%3.74%7.42%1 Year Performance-65.55%5.72%33.78%21.48% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.0802 of 5 stars$2.68+5.5%$23.80+788.1%-66.0%$55.88M$1M-0.42190CRGXCARGO Therapeutics2.3266 of 5 stars$4.12-1.7%$15.00+264.1%-71.9%$193.20MN/A-0.89116News CoverageAnalyst ForecastCYBNCybin2.9239 of 5 stars$8.39+2.9%$86.00+925.0%N/A$193.17MN/A-1.9250Analyst ForecastEDITEditas Medicine4.0586 of 5 stars$2.20-3.5%$4.70+113.6%-37.3%$190.87M$32.31M-0.72230EPRXEupraxia Pharmaceuticals2.2141 of 5 stars$5.76+8.7%$11.00+91.0%+106.0%$190.57MN/A-7.5829Positive NewsGap UpHigh Trading VolumeENGNenGene2.7897 of 5 stars$3.64-0.5%$23.29+539.7%-57.5%$187.04MN/A-2.2131Trending NewsTLSATiziana Life Sciences0.8186 of 5 stars$1.58-1.3%N/A+86.2%$186.96MN/A0.008News CoverageCTMXCytomX Therapeutics3.834 of 5 stars$2.27+0.9%$5.33+134.9%+84.4%$181.40M$138.10M4.73170News CoverageOGIOrganigram Global0.9804 of 5 stars$1.35flatN/A-8.3%$180.82M$117.47M13.50860News CoverageGNFTGENFIT1.511 of 5 stars$3.73+3.2%$13.00+249.0%-12.2%$180.49M$67.00M0.00120News CoverageGap UpFDMT4D Molecular Therapeutics2.1288 of 5 stars$3.71-3.4%$29.56+696.6%-80.5%$177.89M$40K-1.17120 Related Companies and Tools Related Companies CRGX Alternatives CYBN Alternatives EDIT Alternatives EPRX Alternatives ENGN Alternatives TLSA Alternatives CTMX Alternatives OGI Alternatives GNFT Alternatives FDMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
